{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:40:56Z","timestamp":1784259656303,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/mph.0b013e3182580d6e","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:24:47Z","timestamp":1371158687000},"page":"480-483","source":"Crossref","is-referenced-by-count":11,"title":["Thalidomide Therapy for Aggressive Histiocytic Lesions in the Pediatric Population"],"prefix":"10.1097","volume":"34","author":[{"given":"Kelly M.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie P.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morand","family":"Piert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"McAllister-Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210227","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1476-5381.1960.tb01217.x","article-title":"Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug.","volume":"15","author":"Somers","year":"1960","journal-title":"Br J Pharmacol Chemother"},{"key":"R2-15-20210227","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1081\/CNV-120002498","article-title":"Thalidomide: an old drug with new clinical applications.","volume":"20","author":"Baidas","year":"2002","journal-title":"Cancer Invest"},{"key":"R3-15-20210227","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1345\/aph.1A098","article-title":"Thalidomide use in pediatric patients.","volume":"36","author":"Bessmertny","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R4-15-20210227","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/qjmed\/hcq206","article-title":"Langerhans cell histiocytosis: old disease and new treatment.","volume":"104","author":"Ng-Chen-Hin","year":"2010","journal-title":"QJM"},{"key":"R5-15-20210227","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pbc.20578","article-title":"Phase II trial using thalidomide for Langerhans cell histiocytosis.","volume":"48","author":"McClain","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R6-15-20210227","first-page":"814","article-title":"Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.","volume":"9","author":"Ladizinski","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"R7-15-20210227","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-15-20210227","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","article-title":"Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.","volume":"28","author":"Hornick","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R9-15-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2559.2002.01418.x","article-title":"Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.","volume":"41","author":"Pileri","year":"2002","journal-title":"Histopathology"},{"key":"R10-15-20210227","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/modpathol.3800346","article-title":"Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163.","volume":"18","author":"Vos","year":"2005","journal-title":"Mod Pathol"},{"key":"R11-15-20210227","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0022-3476(96)70247-0","article-title":"Juvenile xanthogranuloma: forms of systemic disease and their clinical implications.","volume":"129","author":"Freyer","year":"1996","journal-title":"J Pediatr"},{"key":"R12-15-20210227","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-0560.1995.tb01415.x","article-title":"Juvenile xanthogranuloma: a clinical, histopathologic and immunohistochemical study.","volume":"22","author":"Sangueza","year":"1995","journal-title":"J Cutan Pathol"},{"key":"R13-15-20210227","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/sj.leu.2403075","article-title":"Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL Leukemia.","volume":"17","author":"Dalle","year":"2003","journal-title":"Leukemia"},{"key":"R14-15-20210227","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ajh.20913","article-title":"Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.","volume":"82","author":"Abidi","year":"2007","journal-title":"Am J Hematol"},{"key":"R15-15-20210227","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2010.32.6603","article-title":"Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature.","volume":"29","author":"Gergis","year":"2011","journal-title":"J Clin Oncol"},{"key":"R16-15-20210227","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/pbc.22756","article-title":"An aggressive systemic juvenile xanthogranuloma clonally related to a preceding T-cell acute lymphoblastic leukemia.","volume":"56","author":"Perez-Becker","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R17-15-20210227","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000478-200305000-00003","article-title":"Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations.","volume":"27","author":"Dehner","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R18-15-20210227","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.21523","article-title":"Treatment of juvenile xanthogranuloma.","volume":"51","author":"Stover","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R19-15-20210227","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies.","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0b013e3182580d6e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:12:57Z","timestamp":1620965577000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201208000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3182580d6e","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}